Prebiotic 2FL-IMO Composition for Gastrointestinal Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal disorders such as IBS, IBD, Crohn's disease, ulcerative colitis, and Celiac disease are ineffective in curing the conditions, often leading to complications and symptom management rather than resolution, and there is a need for a more effective approach to reduce inflammation in the gastrointestinal tract.
Innovation Solution
A prebiotic composition comprising a combination of 2'fucosyllactose (2'FL) and isomaltooligosaccharide (IMO) in specific weight ratios, which is used in foodstuff, beverages, or kits to reduce or suppress inflammation in the gastrointestinal tract, promoting the growth of beneficial bacteria and producing short-chain fatty acids to inhibit harmful microorganisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacologic treatments are used for gastrointestinal disorders, then symptoms can be managed, but the conditions cannot be cured and complications arise
Solution Approach 1:
The patent converts the harmful effect of dysbiosis (altered microbiota) into a beneficial outcome by using prebiotic compositions to restore balanced microbiota. The prebiotics promote growth of beneficial bacteria that produce anti-inflammatory short-chain fatty acids, thereby transforming the pathological state into a therapeutic one and achieving curative effectiveness without treatment complications.
Solution Approach 2:
The patent employs a composite prebiotic composition containing multiple oligosaccharides (2'-fucosyllactose, isomaltooligosaccharide, and/or galactooligosaccharide) that work synergistically. This composite approach enhances curative effectiveness by targeting multiple aspects of microbiota restoration simultaneously, while avoiding the complications associated with single-agent pharmacologic treatments.
2Object-affected harmful factors
If prebiotic composition is used to promote beneficial bacteria growth, then inflammation is reduced, but specific dosage ratios must be maintained
Solution Approach 1:
The patent specifies precise parameter ranges for oligosaccharide concentrations and ratios (2'-fucosyllactose: 0.1-10 g/day, isomaltooligosaccharide: 0.1-10 g/day, galactooligosaccharide: 0.1-10 g/day, with weight ratios of 1:9 to 9:1). These parameter definitions enable effective inflammation reduction while providing clear manufacturing guidelines to maintain therapeutic efficacy.
Solution Approach 2:
The patent applies different oligosaccharide components with specific functions at different proportions. Each oligosaccharide type has distinct prebiotic properties that target specific aspects of microbiota modulation, allowing optimized local effects within the composite composition to maximize anti-inflammatory benefits while managing manufacturing precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The prebiotic composition effectively reduces gastrointestinal inflammation, improves quality of life, increases beneficial bacteria levels, and decreases pathogenic microorganisms, as demonstrated by increased short-chain fatty acid production and improved gastrointestinal health in clinical studies.
Implementation Method 1
a prebiotic composition comprising a combination of 2'fucosyllactose (2'FL) and isomaltooligosaccharide (IMO)... promoting the growth of beneficial bacteria and producing short-chain fatty acids
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
Disclosed is a prebiotic composition comprising a combination of 2'fucosyllactose (2'FL) and isomaltooligosaccharide (IMO). The 2'FL and IMO are present in the prebiotic composition in a weight ratio of from 1:1 to 1:10. The prebiotic composition is effective for use in methods of preventing and/or treating a gastrointestinal (GI) condition in an animal, such as irritable bowel syndrome (IBS), inflammatory bowel disease(s) (IBD), Crohn's disease, and ulcerative colitis (UC). A foodstuff or beverage, a medical food, a nutritional composition, and a kit presentation, each including the prebiotic composition, and each suitable for use in methods of reducing or suppressing inflammation in an animalian tract, are also disclosed. A method of using the prebiotic composition to prevent and/or treat a GI condition in an animal is further disclosed. The method comprises administering the prebiotic composition to the animal.